Posts

Recent Advances in Wearable Biosensor Development Programs in 2026

In February 2026, Sava Technologies reported early clinical results for a microsensor-based continuous glucose monitor (CGM) involving 46 participants with diabetes, showing reliable measurements over 10 days. 1 Washington State University developed a wearable biosensor using microneedles and signal amplification to minimize skin discomfort; the team filed a provisional patent and is advancing to preclinical testing. 1 The EU-backed H2TRAIN project is developing sweat biosensors using graphene oxide, integrated with edge-cloud AI for biomarker analysis like lactate, cortisol, and C-reactive protein. 1 Smart contact lenses in 2026 enable non-invasive tear biomarker analysis for glucose and systemic health, building on 2024 research in Nature Communications. 1 2 Wearable biosensors market is projected to grow from USD 29.6 billion in 2023 to USD 65.4 billion by 2033 at a CAGR of 8.2%, driven by real-time health monitoring. 4 Biosensors market expected to expand from USD 35.46 b...

Fierce Biotech Layoff Tracker 2026: Amgen Lays Off 22 Horizon Staffers

Voyager Therapeutics Pauses Alzheimer's APOE Program 8 Months After Unveiling

NAMs-Related Presentations at the Upcoming 65th SOT Annual Meeting in San Diego

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment

Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

Incyte Receives FDA CRL for Zynyz NSCLC Expansion Due to Issues at Novo Nordisk's Catalent Indiana Facility, Becoming Third Affected Company

FDA Approves Leucovorin for Rare Cerebral Folate Deficiency Without New Trial Data

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

Ascletis Reports Positive Phase 2 Data for Quarterly-Dosing GLP-1 ASC30 in Obesity

Alfasigma Licenses GSK's Linerixibat for PBC Itch in Up to $690M Deal